PDF(Pubmed)
Abstract：
Aims: This study investigates the activity of the broad-spectrum bacteriocin nisin against a large panel of Gram-negative bacterial isolates, including relevant plant, animal, and human pathogens. The aim is to generate supportive evidence towards the use/inclusion of bacteriocin-based therapeutics and open avenues for their continued development. Methods and Results: Nisin inhibitory activity was screened against a panel of 575 strains of Gram-negative bacteria, encompassing 17 genera. Nisin inhibition was observed in 309 out of 575 strains, challenging the prevailing belief that nisin lacks effectiveness against Gram-negative bacteria. The genera Acinetobacter, Helicobacter, Erwinia, and Xanthomonas exhibited particularly high nisin sensitivity. Conclusions: The findings of this study highlight the promising potential of nisin as a therapeutic agent for several key Gram-negative plant, animal, and human pathogens. These results challenge the prevailing notion that nisin is less effective or ineffective against Gram-negative pathogens when compared to Gram-positive pathogens and support future pursuits of nisin as a complementary therapy to existing antibiotics. Significance and Impact of Study: This research supports further exploration of nisin as a promising therapeutic agent for numerous human, animal, and plant health applications, offering a complementary tool for infection control in the face of multidrug-resistant bacteria.
摘要：
目的：这项研究调查了广谱细菌素乳酸链球菌素对一大批革兰氏阴性细菌分离株的活性，包括相关工厂，动物,和人类病原体。目的是为使用/包含基于细菌素的疗法提供支持性证据，并为其持续发展开辟道路。方法和结果:对一组575株革兰氏阴性菌进行Nisin抑制活性筛选,涵盖17属。在575个菌株中的309个中观察到Nisin抑制，挑战了流行的观点，即乳酸链球菌素缺乏对革兰氏阴性细菌的有效性。不动杆菌属,螺杆菌,Erwinia,和黄单胞菌表现出特别高的乳酸链球菌素敏感性。结论：这项研究的结果强调了乳酸链球菌素作为几种关键革兰氏阴性植物的治疗剂的有希望的潜力，动物,和人类病原体。这些结果挑战了流行的观念，即与革兰氏阳性病原体相比，乳链菌肽对革兰氏阴性病原体的有效性或无效性较差，并支持未来对乳链菌肽作为现有抗生素的补充疗法的追求。研究的意义和影响：这项研究支持进一步探索乳酸链球菌素作为一种有前途的治疗药物，动物,和植物健康应用，在面对多重耐药细菌时，为感染控制提供了补充工具。
